Clinical Validation of Unani Pharmacopoeial Formulation Laooq-e- Zeequn Nafas in Zeequn Nafas (Bronchial Asthma)

Central Council for Research in Unani Medicine CCRUM New Delhi0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Males and females of 18-65 years.
•2.Patients of Bronchial Asthma for at least 6 months presenting with at least one of the following symptoms:
•b.Shortness of breath
•c.Chest tightness and cough that vary over time and in intensity,
•d.Expiratory airflow limitation as suggested by
•a decreased FEV1
•3.Objective evidence for reversible airway obstruction (>=12% and >=200 mL change in FEV1 and/or a 25% and 60 L/min change in PEFR) either spontaneously or after treatment.
•4.Patients with Asthma Control Questionnaire Score > 1.5.

•1.FEV1/FVC ratio < 50%
•2.Pregnant and lactating mother
•3.Patient with other Respiratory Tract Infections, tuberculosis and malignancy.
•4.Patient of Presence of chronic cough with expectoration for 2-3 months in each of 2 successive years.
•5.Patient with co-morbidities, Diabetes Mellitus, Hepatic and Renal Insufficiency.
•6.Patients with Tobacco Smoking.
•7.Patient with regular use of oral or systemic corticosteroids for conditions other than Asthma.

发起方

Central Council for Research in Unani Medicine CCRUM New Delhi